A 2026 review outlines the shift in solid organ transplantation from broad immunosuppression to Treg-based active tolerance. It covers polyclonal Tregs, CAR-Tregs and CRISPR-edited off-the-shelf products.
China's regulatory reforms since 2015 have streamlined clinical trial and drug approval processes, accelerating development of advanced therapies like CAR-T and bispecific antibodies. These changes have boosted investor confidence and created opportunities for global pharmaceutical partnerships with Chinese biotech companies that have innovative pipelines but lack international marketing capabilities.
Pharmaceutical M&A is shifting toward late-stage clinical assets with proven human data, particularly in GLP-1 obesity drugs, oncology, and central nervous system disorders. Companies like Viking Therapeutics, Structure Therapeutics, and Revolution Medicines represent compelling acquisition targets with advanced clinical programs. This trend reflects industry prioritization of de-risked assets that can accelerate commercialization pathways.
Market analysis reports project substantial growth through 2033 across sarcopenia treatments, oncology injection drugs, and ASO-based therapies. Major pharmaceutical companies including Pfizer, Merck, Roche, Novartis, and Amgen feature prominently across all three therapeutic areas. The reports cover market segmentation, geographic analysis, and competitive landscapes for each sector.
Kelun-Biotech reported 2025 revenue of RMB2.06 billion with four products now marketed in China. The company's TROP2 ADC received multiple regulatory approvals for breast and lung cancer indications. A Phase 3 trial combining the ADC with pembrolizumab met its primary endpoint in first-line NSCLC treatment.
Recent studies reveal metformin's varied effects: it may extend lifespan in older women with diabetes by 30 percent, but failed to improve long COVID symptoms when given after infection developed.
More than 16,000 dermatology trials were completed, ongoing, or planned by the end of 2025, with the Asia-Pacific region experiencing a nearly five-fold increase over the past decade. The field now accounts for around 8,000 trials in Asia-Pacific alone, matching North America and Europe combined.
International Rare Disease Day on February 28 underscores challenges in diagnosing and treating rare genetic conditions, with patients facing years-long diagnostic delays and geographic barriers to accessing gene therapies.
Zydus Lifesciences launched ANYRA, India's first indigenous Aflibercept biosimilar for retinal conditions, and secured approval for a March 2026 day-one launch of generic semaglutide for diabetes and obesity treatment.
The FDA has granted Fast Track designation to PLT012, a first-in-class anti-CD36 monoclonal antibody for hepatocellular carcinoma treatment. The Phase 1 trial is currently enrolling patients in Texas.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07603505 |
Effect of NAE on Polycystic Ovarian Syndrome (PCOS) |
RECRUITING | PHASE1 |
| NCT07576777 |
Hormonal and Microbiota Modulation After Endoscopic Sleeve Gastroplasty |
NOT_YET_RECRUITING | NA |
| NCT07562724 |
Diet and WB-EMS Effects in Obesity |
NOT_YET_RECRUITING | NA |
| NCT07512609 |
Environment, Inflammation and Metabolic Diseases Study |
RECRUITING | |
| NCT07471607 |
Safety and Effectiveness of Overripe Banana Powder Added to Diabetic Formulas in Type 2 Diabetes |
COMPLETED | NA |
| NCT07388537 |
Evaluation of the Clinical Spectrum of Diabetes and Obesity in Youth and Adults |
NOT_YET_RECRUITING | |
| NCT07361887 |
Deciphering the Effect of Moderate Wine Consumption on Healthy Aging Through Postprandial Extracellular Vesicles. |
RECRUITING | NA |
| NCT07309913 |
China Atrial Fibrillation With Complex Metabolic Disorder Cohort Study (CAME Cohort) |
NOT_YET_RECRUITING | |
| NCT07206875 |
Observational Study for the Characterisation of Patients Affected by Any Type of Diabetes and Endocrine Disorders |
NOT_YET_RECRUITING | |
| NCT07161557 |
Evaluating Metabolic Health in People Aged 18 to 60 by Nutrilite Metabolic Health Index |
NOT_YET_RECRUITING |
